


TEEMS CONSORT Flow Diagram

Screening

Allocated group

Follow-up

Primary outcome



Full demographics and vital signs

Table x: Demographics at screening (all recruited participants)

	Study Arm			
	A	B	C	Total
	N=46	N=31	N=30	N=107
Age (years)				
N	46	31	30	107
Mean (SD)	54.1 (13.9)	49.9 (13.7)	47.6 (11.4)	51.0 (13.4)
Median (IQR)	52.5 (44.0 - 66.0)	50.0 (40.0 - 59.0)	50.5 (39.0 - 56.0)	51.0 (42.0 - 59.0)
Min-Max	28.0 - 80.0	20.0 - 76.0	27.0 - 66.0	20.0 - 80.0
Gender				
Female	28 (60.9%)	25 (80.6%)	23 (76.7%)	76 (71.0%)
Male	18 (39.1%)	6 (19.4%)	7 (23.3%)	31 (29.0%)
Ethnicity				
White	37 (80.4%)	27 (87.1%)	19 (63.3%)	83 (77.6%)
Asian or Asian British	0 (0.0%)	0 (0.0%)	3 (10.0%)	3 (2.8%)
Mixed or multiple ethnic groups	2 (4.3%)	1 (3.2%)	1 (3.3%)	4 (3.7%)
Other ethnic group	5 (10.9%)	2 (6.5%)	4 (13.3%)	11 (10.3%)
Prefer not to say	2 (4.3%)	1 (3.2%)	3 (10.0%)	6 (5.6%)
Family History of Auto Immune Disease				
No	28 (60.9%)	20 (64.5%)	16 (53.3%)	64 (59.8%)
Yes	17 (37.0%)	11 (35.5%)	14 (46.7%)	42 (39.3%)
Unknown	1 (2.2%)	0 (0.0%)	0 (0.0%)	1 (0.9%)
Smoking Status				
Current	8 (17.4%)	7 (22.6%)	6 (20.0%)	21 (19.6%)
Previous	25 (54.3%)	13 (41.9%)	14 (46.7%)	52 (48.6%)
Never	13 (28.3%)	11 (35.5%)	10 (33.3%)	34 (31.8%)
Alcohol Intake (units/week)				
N	46	31	30	107
Mean (SD)	4.3 (6.5)	4.5 (6.9)	5.5 (10.0)	4.7 (7.7)
Median (IQR)	2.0 (0.0 - 6.0)	1.0 (0.0 - 10.0)	2.0 (0.0 - 5.0)	1.0 (0.0 - 6.0)
Min-Max	0.0 - 32.0	0.0 - 30.0	0.0 - 48.0	0.0 - 48.0

Table x: Vital Signs/Observations at screening (all recruited participants)

	Study Arm			
	A	B	C	Total
	N=46	N=31	N=30	N=107
Pulse (/min)				
N	46	31	30	107
Mean (SD)	73.0 (11.7)	74.6 (12.5)	76.9 (10.7)	74.6 (11.7)
Median (IQR)	72.0 (64.0 - 81.0)	74.0 (65.0 - 81.0)	75.0 (70.0 - 82.0)	74.0 (66.0 - 82.0)

Min-Max	51.0 - 99.0	56.0 - 112.0	60.0 - 109.0	51.0 - 112.0
Systolic Blood Pressure (mmHg)				
N	46	31	30	107
Mean (SD)	135.5 (16.1)	126.5 (13.5)	125.5 (16.2)	130.1 (16.0)
Median (IQR)	135.0 (124.0 - 144.0)	124.0 (118.0 - 133.0)	124.5 (112.0 - 140.0)	129.0 (118.0 - 142.0)
Min-Max	110.0 - 176.0	103.0 - 159.0	97.0 - 159.0	97.0 - 176.0
Diastolic Pressure (mmHg)				
N	46	31	30	107
Mean (SD)	81.9 (10.9)	79.9 (6.2)	79.6 (7.7)	80.7 (8.9)
Median (IQR)	80.5 (76.0 - 89.0)	81.0 (77.0 - 84.0)	80.0 (72.0 - 84.0)	81.0 (76.0 - 85.0)
Min-Max	58.0 - 125.0	68.0 - 91.0	61.0 - 94.0	58.0 - 125.0
Temperature (°C)				
N	46	31	30	107
Mean (SD)	36.5 (0.4)	36.6 (0.4)	36.6 (0.5)	36.6 (0.5)
Median (IQR)	36.5 (36.3 - 36.8)	36.7 (36.3 - 36.8)	36.6 (36.4 - 37.0)	36.6 (36.3 - 36.8)
Min-Max	35.5 - 37.6	35.6 - 37.4	35.5 - 37.7	35.5 - 37.7
Weight (kg)				
N	45	31	30	106
Mean (SD)	82.8 (15.9)	79.6 (15.6)	83.0 (20.8)	81.9 (17.2)
Median (IQR)	82.8 (71.2 - 91.0)	78.0 (68.0 - 91.6)	79.0 (67.0 - 93.0)	80.6 (69.9 - 92.0)
Min-Max	49.0 - 125.0	50.0 - 110.0	52.0 - 146.0	49.0 - 146.0
Height (m)				
N	46	29	30	105
Mean (SD)	1.7 (0.1)	1.7 (0.1)	1.7 (0.1)	1.7 (0.1)
Median (IQR)	1.6 (1.6 - 1.8)	1.6 (1.6 - 1.7)	1.6 (1.6 - 1.7)	1.6 (1.6 - 1.7)
Min-Max	1.5 - 2.0	1.6 - 1.9	1.5 - 1.9	1.5 - 2.0
BMI (kg/m²)				
N	45	29	30	104
Mean (SD)	29.5 (6.1)	28.8 (5.4)	30.4 (7.6)	29.6 (6.4)
Median (IQR)	27.8 (25.7 - 33.3)	28.0 (24.1 - 31.5)	29.5 (25.0 - 34.2)	28.2 (24.9 - 33.1)
Min-Max	21.1 - 46.5	20.3 - 41.9	21.0 - 51.0	20.3 - 51.0
Duration of Early Morning Stiffness (minutes)				
N	46	31	30	107
Mean (SD)	140.9 (194.1)	100.5 (134.3)	124.4 (170.8)	124.6 (171.3)
Median (IQR)	60.0 (30.0 - 120.0)	60.0 (30.0 - 120.0)	75.0 (30.0 - 120.0)	60.0 (30.0 - 120.0)
Min-Max	0.0 - 720.0	0.0 - 720.0	2.0 - 720.0	0.0 - 720.0

Primary Analysis Participants

Table x: Demographics at Screening- all analysed participants only (FAS)

	Study Arm			
	A	B	C	Total
	N=45	N=29	N=29	N=103
Age (years)				
N	45	29	29	103
Mean (SD)	54.2 (14.0)	49.4 (13.8)	47.0 (11.3)	50.8 (13.5)
Median (IQR)	53.0 (44.0 - 66.0)	50.0 (40.0 - 58.0)	50.0 (39.0 - 56.0)	51.0 (40.0 - 59.0)
Min-Max	28.0 - 80.0	20.0 - 76.0	27.0 - 66.0	20.0 - 80.0
Gender				
Female	27 (60.0%)	23 (79.3%)	22 (75.9%)	72 (69.9%)
Male	18 (40.0%)	6 (20.7%)	7 (24.1%)	31 (30.1%)
Ethnicity				
White	36 (80.0%)	25 (86.2%)	18 (62.1%)	79 (76.7%)
Asian or Asian British	0 (0.0%)	0 (0.0%)	3 (10.3%)	3 (2.9%)
Mixed or multiple ethnic groups	2 (4.4%)	1 (3.4%)	1 (3.4%)	4 (3.9%)
Other ethnic group	5 (11.1%)	2 (6.9%)	4 (13.8%)	11 (10.7%)
Prefer not to say	2 (4.4%)	1 (3.4%)	3 (10.3%)	6 (5.8%)
Family History of Auto Immune Disease				
No	28 (62.2%)	20 (69.0%)	15 (51.7%)	63 (61.2%)
Yes	16 (35.6%)	9 (31.0%)	14 (48.3%)	39 (37.9%)
Unknown	1 (2.2%)	0 (0.0%)	0 (0.0%)	1 (1.0%)
Smoking Status				
Current	8 (17.8%)	6 (20.7%)	6 (20.7%)	20 (19.4%)
Previous	24 (53.3%)	12 (41.4%)	13 (44.8%)	49 (47.6%)
Never	13 (28.9%)	11 (37.9%)	10 (34.5%)	34 (33.0%)
Alcohol Intake (units/week)				
N	45	29	29	103
Mean (SD)	4.4 (6.6)	4.7 (7.1)	5.6 (10.1)	4.8 (7.8)
Median (IQR)	2.0 (0.0 - 6.0)	1.0 (0.0 - 10.0)	2.0 (0.0 - 5.0)	2.0 (0.0 - 6.0)
Min-Max	0.0 - 32.0	0.0 - 30.0	0.0 - 48.0	0.0 - 48.0

Table x: Vital Signs/Observations at Screening - all analysed participants only (FAS)

	Study Arm			
	A	B	C	Total
	N=45	N=29	N=29	N=103
Pulse (/min)				
N	45	29	29	103
Mean (SD)	73.0 (11.8)	73.9 (12.7)	77.1 (10.8)	74.4 (11.8)
Median (IQR)	72.0 (64.0 - 81.0)	74.0 (65.0 - 79.0)	75.0 (70.0 - 82.0)	74.0 (66.0 - 82.0)
Min-Max	51.0 - 99.0	56.0 - 112.0	60.0 - 109.0	51.0 - 112.0
Systolic Blood Pressure (mmHg)				
N	45	29	29	103
Mean (SD)	135.3 (16.3)	127.1 (13.7)	126.4 (15.6)	130.5 (15.8)
Median (IQR)	135.0 (124.0 - 144.0)	124.0 (119.0 - 133.0)	125.0 (112.0 - 140.0)	129.0 (118.0 - 142.0)
Min-Max	110.0 - 176.0	103.0 - 159.0	103.0 - 159.0	103.0 - 176.0
Diastolic Pressure (mmHg)				
N	45	29	29	103
Mean (SD)	81.6 (10.9)	80.0 (6.0)	80.0 (7.5)	80.7 (8.8)
Median (IQR)	80.0 (76.0 - 89.0)	81.0 (78.0 - 83.0)	80.0 (74.0 - 84.0)	81.0 (76.0 - 84.0)
Min-Max	58.0 - 125.0	68.0 - 91.0	61.0 - 94.0	58.0 - 125.0
Temperature (°C)				
N	45	29	29	103
Mean (SD)	36.5 (0.4)	36.6 (0.4)	36.6 (0.5)	36.6 (0.5)
Median (IQR)	36.5 (36.3 - 36.8)	36.7 (36.5 - 36.8)	36.7 (36.4 - 37.0)	36.6 (36.3 - 36.8)
Min-Max	35.5 - 37.6	35.6 - 37.4	35.5 - 37.7	35.5 - 37.7
Weight (kg)				
N	44	29	29	102
Mean (SD)	83.1 (15.9)	78.4 (15.3)	81.4 (19.2)	81.3 (16.7)
Median (IQR)	83.4 (72.6 - 92.2)	77.2 (68.0 - 88.0)	78.0 (67.0 - 92.0)	80.2 (69.9 - 91.0)
Min-Max	49.0 - 125.0	50.0 - 110.0	52.0 - 146.0	49.0 - 146.0
Height (m)				
N	45	27	29	101
Mean (SD)	1.7 (0.1)	1.7 (0.1)	1.7 (0.1)	1.7 (0.1)
Median (IQR)	1.6 (1.6 - 1.8)	1.7 (1.6 - 1.7)	1.6 (1.6 - 1.7)	1.6 (1.6 - 1.7)
Min-Max	1.5 - 2.0	1.6 - 1.9	1.5 - 1.9	1.5 - 2.0
BMI (kg/m²)				
N	44	27	29	100
Mean (SD)	29.6 (6.2)	28.2 (5.1)	29.7 (6.7)	29.2 (6.0)
Median (IQR)	28.2 (25.4 - 33.5)	28.0 (24.0 - 30.2)	29.5 (25.0 - 33.1)	28.0 (24.8 - 32.2)
Min-Max	21.1 - 46.5	20.3 - 41.9	21.0 - 49.3	20.3 - 49.3
Duration of Early Morning Stiffness (minutes)				
N	45	29	29	103
Mean (SD)	141.3 (196.2)	99.1 (138.0)	127.7 (172.9)	125.6 (174.2)
Median (IQR)	60.0 (30.0 - 120.0)	60.0 (30.0 - 120.0)	90.0 (60.0 - 120.0)	60.0 (30.0 - 120.0)

Min-Max	0.0 - 720.0	0.0 - 720.0	2.0 - 720.0	0.0 - 720.0
---------	-------------	-------------	-------------	-------------

Primary Outcome

Table x: DAS-28 and clinical remission descriptive summaries (FAS)

	Study Arm			
	A	B	C	Total
	N=45	N=29	N=29	N=103
Baseline				
DAS-28 Score				
N	45	29	29	103
Missing	0	0	0	0
Mean (SD)	5.0 (1.5)	5.4 (1.4)	5.2 (1.3)	5.2 (1.4)
Median (IQR)	5.3 (3.6-6.1)	5.6 (4.4-6.4)	5.0 (4.6-5.5)	5.3 (4.1-6.2)
Min-Max	2.4-8.2	2.0-7.6	3.0-8.2	2.0-8.2
Clinical Remission Rate				
Not achieved	44 (97.8%)	28 (96.6%)	29 (100.0%)	101 (98.1%)
Achieved	1 (2.2%)	1 (3.4%)	0 (0.0%)	2 (1.9%)
Week 4				
DAS-28 Score				
N	41	27	27	95
Missing	4	2	2	8
Mean (SD)	3.3 (1.7)	4.1 (1.3)	3.3 (1.2)	3.5 (1.5)
Median (IQR)	3.0 (2.0-4.6)	4.2 (3.4-4.9)	3.2 (2.5-4.1)	3.4 (2.5-4.6)
Min-Max	0.5-6.7	1.2-6.7	1.2-7.2	0.5-7.2
Clinical Remission Rate (missing imputed as not achieved)				
Not achieved	27 (60.0%)	27 (93.1%)	20 (69.0%)	74 (71.8%)
Achieved	18 (40.0%)	2 (6.9%)	9 (31.0%)	29 (28.2%)
Week 12				
DAS-28 Score				
N	43	27	28	98
Missing	2	2	1	5
Mean (SD)	3.5 (1.5)	3.8 (1.3)	3.1 (1.6)	3.5 (1.5)
Median (IQR)	3.6 (2.2-4.4)	3.7 (2.8-4.4)	2.7 (2.1-3.8)	3.5 (2.5-4.3)
Min-Max	0.5-7.0	1.7-7.1	0.6-7.0	0.5-7.1
Clinical Remission Rate (missing imputed as not achieved)				
Not achieved	34 (75.6%)	26 (89.7%)	15 (51.7%)	75 (72.8%)
Achieved	11 (24.4%)	3 (10.3%)	14 (48.3%)	28 (27.2%)
Week 24				
DAS-28 Score				
N	43	27	27	97
Missing	2	2	2	6
Mean (SD)	3.2 (1.4)	3.5 (1.2)	3.0 (1.6)	3.2 (1.4)
Median (IQR)	2.9 (1.9-4.0)	3.4 (2.3-4.2)	2.9 (1.7-3.7)	3.3 (2.1-4.0)
Min-Max	0.6-6.8	1.4-7.2	0.1-7.5	0.1-7.5
Clinical Remission Rate (missing imputed as not achieved)				
Not achieved	27 (60.0%)	22 (75.9%)	18 (62.1%)	67 (65.0%)
Achieved	18 (40.0%)	7 (24.1%)	11 (37.9%)	36 (35.0%)

Primary Analysis

Table x: Primary outcome results, note that marginal adjusted proportions are reported but conditional odds ratios are reported (FAS)

	N	Adjusted Proportions	Adjusted Difference in Proportions [95% CI]	Unadjusted OR [95% CI]	P-value (unadjusted model)	Adjusted OR [95% CI]	P-value (adjusted model)
Week 12							
Arm A	45	0.21	0.06 [-0.1, 0 .21]	2.8 [0.71, 11.09]	0.14	1.85 [0.36, 9.56]	0.46
Arm B	29	0.15					
Week 24							
Arm A	45	0.35	0.04 [-0.17, 0.26]	2.1 [0.74, 5.92]	0.16	1.27 [0.39, 4.12]	0.69
Arm B	29	0.31					

Secondary Outcomes

Clinical Remission (B vs C, 12 and 24 weeks)

Table x: B vs C clinical remission results, note that marginal adjusted proportions are reported but conditional odds ratios are reported (FAS)

Study Arm	N	Adjusted Proportions	Adjusted Difference in Proportions [95% CI]	Unadjusted OR [95% CI]	Adjusted OR	P-value
Week 12						
B	29	0.15				
C	29	0.46	0.32 95% CI [0.12,0.51] 90% CI[0.15 ,0.48] 85% CI[0.17 ,0.46] 75% CI[0.21 ,0.43]	8.09 95% CI [2.00, 32.79] 90% CI[2.5, 26.18] 85% CI[2.89, 22.61] 75% CI[3.56, 18.39]	11.09 95% CI[2.13, 57.89] 90% CI[2.77, 44.38] 85% CI[3.3, 37.33] 75% CI[4.21, 29.25]	<0.01
Week 24						
B	29	0.31				
C	29	0.39	0.09 95% CI [-0.13,0.32] 90% CI[-0.01, 0.29] 85% CI[-0.08, 0.27] 75% CI[-0.05 ,0 .23]	1.92 95% CI [0.62, 5.97] 90% CI[0.74, 4.97] 85% CI[0.84, 4.42] 75% CI[0.99, 3.74]	1.62 95% CI[0.46, 5.65] 90% CI[0.57, 4.62] 85% CI[0.65, 4.05] 75% CI[0.78, 3.37]	0.45

Sustained Clinical Remission

Table X: Sustained clinical remission descriptive summaries (FAS)

	Study arm			
	A	B	C	Total
	N=45	N=29	N=29	N=103
Sustained clinical remission at 12 & 24 weeks*				
Not sustained	36 (80.0%)	26 (89.7%)	19 (65.5%)	81 (78.6%)
Sustained	9 (20.0%)	3 (10.3%)	10 (34.5%)	22 (21.4%)

*Missing data assumed as non-responders

Table X: Results from the logistic regression model assessing sustained clinical remission note that marginal adjusted proportions are reported but conditional odds ratios are reported (FAS)

Study Arm	N	Adjusted Proportion	Adjusted Difference in Proportions	Unadjusted OR	Adjusted OR	P-value
A	45	0.16	0.01 [-0.16, 0.15]	2.17 [0.53, 8.79]	1.12 [0.22, 5.64]	0.89
B	29	0.15				
C	29	0.35	0.19 95% CI [-0.02, 0.38] 90% CI [0.03, .35] 85% CI [0.05, .33] 75% CI [0.07, 0.31]	4.56 95% CI [1.1, 18.86] 90% CI [1.39, 15.01] 85% CI [1.61, 12.94] 75% CI [1.98, 10.49]	4.42 95% CI [0.91, 21.37] 90% CI [1.18, 16.59] 85% CI [1.39, 14.06] 75% CI [1.75, 11.15]	0.06

Patient Reported Outcome Measures (PROMS)

EMS

Table x: EMS descriptive summaries (FAS)

Summary	Arm A N=45	Arm B N=29	Arm C N=29	Total N=103
Baseline				
n	45	29	29	103
Mean (SD)	152.3 (217.4)	118.8 (177.1)	82.0 (61.0)	123.1 (175.7)
Median	60.0	60.0	60.0	60.0
Q1,Q3	30.0, 180.0	20.0, 120.0	45.0, 120.0	30.0, 120.0
Min-Max	0.0 - 720.0	0.0 - 720.0	2.0 - 240.0	0.0 - 720.0
Week 4				
n	45	29	27	101
Mean (SD)	55.3 (96.3)	57.0 (133.1)	26.1 (40.8)	48.0 (98.2)
Median	20.0	20.0	5.0	15.0
Q1,Q3	0.0, 60.0	2.0, 60.0	0.0, 60.0	0.0, 60.0
Min-Max	0.0 - 520.0	0.0 - 720.0	0.0 - 180.0	0.0 - 720.0
Week 12				
n	44	29	28	101
Mean (SD)	72.3 (151.2)	27.1 (37.5)	23.6 (38.8)	45.8 (105.7)
Median	12.5	15.0	0.0	10.0
Q1,Q3	1.0, 60.0	0.0, 30.0	0.0, 37.5	0.0, 60.0
Min-Max	0.0 - 720.0	0.0 - 150.0	0.0 - 120.0	0.0 - 720.0
Week 24				
n	43	28	27	98
Mean (SD)	53.0 (114.8)	20.9 (33.3)	36.1 (137.3)	39.1 (106.0)
Median	10.0	5.5	2.0	5.0
Q1,Q3	0.0, 60.0	0.0, 30.0	0.0, 30.0	0.0, 30.0
Min-Max	0.0 - 720.0	0.0 - 120.0	0.0 - 720.0	0.0 - 720.0
P-value+	0.294		0.557	

+ p-value is for the comparison of A or C compared to B at week 24

VAS

Physician Global Assessment of general health

Table x: Physician global assessment of general health VAS descriptive summaries (FAS)

Summary	Arm A N=45	Arm B N=29	Arm C N=29	Total N=103
Baseline				
n	45	29	29	103
Mean (SD)	62.8 (16.8)	63.3 (19.1)	68.3 (18.5)	64.5 (17.9)
Median	70.0	70.0	70.0	70.0
Q1,Q3	50.0, 75.0	60.0, 75.0	60.0, 80.0	50.0, 80.0
Min-Max	20.0 - 85.0	10.0 - 90.0	30.0 - 95.0	10.0 - 95.0
Week 4				
n	43	29	28	100
Mean (SD)	29.3 (22.1)	38.6 (19.5)	23.1 (18.7)	30.3 (21.1)
Median	20.0	40.0	20.0	27.5
Q1,Q3	10.0, 50.0	25.0, 50.0	10.0, 30.0	10.0, 45.0
Min-Max	2.0 - 80.0	10.0 - 80.0	2.0 - 90.0	2.0 - 90.0
Week 12				
n	44	29	28	101
Mean (SD)	26.4 (16.1)	32.1 (23.9)	18.3 (16.1)	25.8 (19.2)
Median	25.0	30.0	15.0	20.0
Q1,Q3	15.0, 40.0	10.0, 50.0	5.0, 27.5	10.0, 40.0
Min-Max	0.0 - 60.0	5.0 - 90.0	0.0 - 70.0	0.0 - 90.0
Week 24				
n	43	28	27	98
Mean (SD)	29.7 (21.6)	24.8 (20.0)	17.4 (17.2)	24.9 (20.5)
Median	30.0	20.0	10.0	20.0
Q1,Q3	10.0, 40.0	10.0, 30.0	5.0, 20.0	10.0, 35.0
Min-Max	1.0 - 80.0	3.0 - 70.0	0.0 - 60.0	0.0 - 80.0
P-value+	0.314		0.059	

+ p-value is for the comparison of A or C compared to B at week 24

Patient Assessment of General State of Health

Table x: Patient Assessment of General State of Health VAS descriptive summaries (FAS)

Summary	Arm A N=45	Arm B N=29	Arm C N=29	Total N=103
Baseline				
n	45	29	29	103
Mean (SD)	47.8 (25.0)	45.6 (21.2)	53.7 (24.9)	48.8 (23.9)
Median	47.0	45.0	56.0	50.0
Q1,Q3	26.0, 63.0	34.0, 56.0	41.0, 74.0	32.0, 63.0
Min-Max	2.0 - 96.0	9.0 - 90.0	1.0 - 95.0	1.0 - 96.0
Week 4				
n	44	28	28	100
Mean (SD)	28.6 (21.2)	29.7 (19.1)	22.4 (14.0)	27.2 (18.9)
Median	23.5	24.5	19.5	23.0
Q1,Q3	10.5, 43.0	16.0, 34.0	10.0, 34.0	13.0, 37.0
Min-Max	1.0 - 86.0	5.0 - 83.0	0.0 - 51.0	0.0 - 86.0
Week 12				
n	43	28	28	99
Mean (SD)	32.4 (22.9)	30.9 (25.3)	21.5 (17.9)	28.9 (22.6)
Median	25.0	22.0	17.5	22.0
Q1,Q3	12.0, 52.0	11.0, 53.0	8.0, 30.0	11.0, 49.0
Min-Max	2.0 - 76.0	3.0 - 87.0	0.0 - 73.0	0.0 - 87.0
Week 24				
n	43	28	27	98
Mean (SD)	31.5 (24.5)	23.3 (19.2)	27.2 (25.3)	28.0 (23.4)
Median	25.0	18.0	20.0	21.0
Q1,Q3	13.0, 47.0	9.0, 30.5	8.0, 40.0	9.0, 39.0
Min-Max	1.0 - 93.0	3.0 - 68.0	0.0 - 82.0	0.0 - 93.0
P-value+	0.181		0.781	

+ p-value is for the comparison of A or C compared to B at week 24

Patient Assessment of Disease Activity

Table x: Patient Assessment of Disease Activity VAS descriptive summaries (FAS)

Summary	Arm A N=45	Arm B N=29	Arm C N=29	Total N=103
Baseline				
n	45	29	29	103
Mean (SD)	57.0 (26.3)	53.0 (22.8)	63.5 (22.1)	57.7 (24.3)
Median	60.0	51.0	67.0	61.0
Q1,Q3	40.0, 78.0	35.0, 70.0	55.0, 79.0	40.0, 78.0
Min-Max	3.0 - 98.0	13.0 - 92.0	7.0 - 97.0	3.0 - 98.0
Week 4				
n	44	28	28	100
Mean (SD)	28.8 (22.0)	29.9 (19.6)	22.0 (16.1)	27.2 (19.9)
Median	25.5	26.5	19.0	23.0
Q1,Q3	11.5, 40.5	13.0, 38.0	10.0, 33.5	12.0, 36.0
Min-Max	1.0 - 79.0	4.0 - 81.0	0.0 - 65.0	0.0 - 81.0
Week 12				
n	43	28	28	99
Mean (SD)	31.7 (24.3)	31.0 (24.1)	22.1 (21.4)	28.8 (23.6)
Median	27.0	24.0	11.5	22.0
Q1,Q3	11.0, 52.0	10.0, 43.5	4.5, 35.5	9.0, 45.0
Min-Max	1.0 - 87.0	2.0 - 77.0	0.0 - 80.0	0.0 - 87.0
Week 24				
n	43	28	27	98
Mean (SD)	31.4 (25.6)	28.5 (23.3)	24.1 (24.5)	28.6 (24.6)
Median	23.0	18.5	14.0	20.5
Q1,Q3	11.0, 51.0	10.0, 47.0	5.0, 39.0	8.0, 46.0
Min-Max	0.0 - 90.0	3.0 - 85.0	0.0 - 84.0	0.0 - 90.0
P-value+	0.621		0.238	

+ p-value is for the comparison of A or C compared to B at week 24

Patient Assessment of Pain

Table x: Patient Assessment of Pain VAS descriptive summaries (FAS)

Summary	Arm A N=45	Arm B N=29	Arm C N=29	Total N=103
Baseline				
n	45	29	29	103
Mean (SD)	49.3 (28.2)	55.7 (23.0)	64.0 (20.5)	55.2 (25.3)
Median	52.0	63.0	66.0	59.0
Q1,Q3	27.0, 71.0	37.0, 72.0	55.0, 78.0	38.0, 72.0
Min-Max	2.0 - 97.0	7.0 - 97.0	7.0 - 94.0	2.0 - 97.0
Week 4				
n	44	28	28	100
Mean (SD)	23.6 (21.6)	29.9 (24.2)	24.6 (23.0)	25.7 (22.7)
Median	19.5	27.0	15.5	18.0
Q1,Q3	6.5, 31.5	10.0, 46.0	6.5, 38.0	7.5, 38.0
Min-Max	0.0 - 91.0	2.0 - 95.0	0.0 - 80.0	0.0 - 95.0
Week 12				
n	43	28	28	99
Mean (SD)	29.1 (25.8)	29.5 (24.4)	25.1 (25.6)	28.1 (25.2)
Median	20.0	24.5	20.0	20.0
Q1,Q3	5.0, 55.0	9.0, 44.0	4.0, 34.5	5.0, 47.0
Min-Max	0.0 - 85.0	2.0 - 83.0	0.0 - 88.0	0.0 - 88.0
Week 24				
n	43	28	27	98
Mean (SD)	28.0 (24.4)	24.8 (23.6)	27.1 (26.6)	26.9 (24.6)
Median	18.0	14.5	21.0	17.5
Q1,Q3	5.0, 48.0	5.5, 36.0	5.0, 55.0	5.0, 46.0
Min-Max	0.0 - 73.0	2.0 - 84.0	0.0 - 78.0	0.0 - 84.0
P-value+	0.711		0.933	

+ p-value is for the comparison of A or C compared to B at week 24

HAQ-DI

Table x: HAQ-DI Descriptive Statistics (FAS)

	Study arm			
	A	B	C	Total
	N=45	N=29	N=29	N=103
Baseline				
N	45	29	29	103
Mean (SD)	1.3 (0.7)	1.5 (0.5)	1.3 (0.8)	1.4 (0.7)
Median (IQR)	1.5 (0.9-1.8)	1.5 (1.2-1.8)	1.1 (0.8-2.0)	1.4 (0.9-1.9)
Min-Max	0.0-2.6	0.5-2.5	0.0-2.5	0.0-2.6
Week 12				
N	43	28	28	99
Mean (SD)	0.9 (0.7)	0.9 (0.6)	0.6 (0.6)	0.8 (0.7)
Median (IQR)	0.9 (0.1-1.4)	0.8 (0.4-1.5)	0.2 (0.0-0.9)	0.8 (0.1-1.4)
Min-Max	0.0-2.1	0.0-2.2	0.0-1.9	0.0-2.2
Week 24				
N	43	28	27	98
Mean (SD)	0.8 (0.7)	0.8 (0.6)	0.5 (0.6)	0.7 (0.6)
Median (IQR)	0.6 (0.2-1.4)	0.6 (0.2-1.2)	0.1 (0.0-0.8)	0.6 (0.1-1.2)
Min-Max	0.0-2.1	0.0-2.2	0.0-1.9	0.0-2.2
P-value+	0.827		0.026	

+ p-value is for the comparison of A or C compared to B at week 24

Imaging Remission

Table x: Imaging Remission Status by study arm (FAS)

	Study arm			
	A	B	C	Total
Baseline				
Attended visit	N=45	N=29	N=29	N=103
Imaging remission not achieved	40 (88.9%)	23 (79.3%)	28 (96.6%)	91 (88.3%)
Imaging remission achieved	4 (8.9%)	5 (17.2%)	1 (3.4%)	10 (9.7%)
Missing	1 (2.2%)	1 (3.4%)	0 (0.0%)	2 (1.9%)
Week 24				
Attended visit	N=43	N=28	N=27	N=98
Imaging remission not achieved	26 (60.5%)	18 (64.3%)	13 (48.1%)	57 (58.2%)
Imaging remission achieved	10 (23.3%)	9 (32.1%)	12 (44.4%)	31 (31.6%)
Missing	7 (16.3%)	1 (3.6%)	2 (7.4%)	10 (10.2%)

Table x: Reasons for missing imaging remission status at baseline and week 24 (FAS)

	Study arm			
	A	B	C	Total
Baseline				
Number missing	1	1	0	2
Reason				
Ultrasound carried out but individual joints missed	1 (100.0%)	1 (100.0%)	0	2 (100.0%)
Week 24				
Number missing	7	1	2	10
Reason				

Missed ultrasound (Sonographer shielding from COVID-19)	1 (14.3%)	0 (0.0%)	0 (0.0%)	1 (10.0%)
Missed ultrasound (reason unknown)	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (10.0%)
Ultrasound carried out but individual joints missed	6 (85.7%)	1 (100.0%)	1 (50.0%)	8 (80.0%)

T-Cell Normalisation

Table x: T cell normalisation status by study arm (note normalisation status were calculated during analysis based off raw naïve t-cell values) (FAS)

	Study arm			
	A	B	C	Total
	N=45	N=29	N=29	N=103
T-cell Normalisation status at screening				
Abnormal	*1 (2.2%)	29 (100.0%)	29 (100.0%)	59 (57.3%)
Normal	44 (97.8%)	0 (0.0%)	0 (0.0%)	44 (42.7%)
T-cell Normalisation status at week 12				
Abnormal	5 (11.1%)	22 (75.9%)	23 (79.3%)	50 (48.5%)
Normal	38 (84.4%)	5 (17.2%)	4 (13.8%)	47 (45.6%)
Missing	2 (4.4%)	2 (6.9%)	2 (6.9%)	6 (5.8%)
T-cell Normalisation status at week 24				

Abnormal	6 (13.3%)	21 (72.4%)	21 (72.4%)	48 (46.6%)
Normal	37 (82.2%)	7 (24.1%)	5 (17.2%)	49 (47.6%)
Missing	2 (4.4%)	1 (3.4%)	3 (10.3%)	6 (5.8%)

*Patient with ID 014 was allocated to Arm A despite having an abnormal naïve T-cell frequency for their age at screening.

Cumulative Corticosteroid Use

Table x: Summary of corticosteroids taken during follow-up (FAS)

Summary	Arm A N=45	Arm B N=29	Arm C N=29	Total N=103
Number of participants who took at least 1 corticosteroid* p-value+	27 (60.0%) 0.633	19 (65.5%)	10 (34.5%) 0.018	56 (54.4%)
Number of corticosteroids	66	36	17	119
*Medication names				
HYDROCORTISONE	1 (1.5%)	1 (2.8%)	0 (0.0%)	2 (1.7%)
METHYLPREDNISOLONE	32 (48.5%)	14 (38.9%)	10 (58.8%)	56 (47.1%)
PREDNISOLONE	25 (37.9%)	17 (47.2%)	5 (29.4%)	47 (39.5%)
TRIAMCINOLONE	8 (12.1%)	4 (11.1%)	2 (11.8%)	14 (11.8%)
*Route				
Intra-articular	1 (1.5%)	0 (0.0%)	1 (5.9%)	2 (1.7%)
Intra-muscular	39 (59.1%)	18 (50.0%)	11 (64.7%)	68 (57.1%)
Oral	25 (37.9%)	17 (47.2%)	5 (29.4%)	47 (39.5%)
Topical	1 (1.5%)	1 (2.8%)	0 (0.0%)	2 (1.7%)
*Frequency				
As needed	1 (1.5%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
Once per day	25 (37.9%)	17 (47.2%)	5 (29.4%)	47 (39.5%)
Once, single dose	39 (59.1%)	18 (50.0%)	12 (70.6%)	69 (58.0%)
Twice per day	0 (0.0%)	1 (2.8%)	0 (0.0%)	1 (0.8%)
Weekly	1 (1.5%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
Days medication taken				
n	66	36	17	119

Mean (SD)	4.5 (11.4)	4.8 (4.7)	2.1 (2.5)	4.2 (9.0)
Median	1.0	3.0	1.0	1.0
Q1,Q3	1.0, 3.0	1.0, 7.0	1.0, 1.0	1.0, 5.0
Min-Max	0.0 - 76.0	1.0 - 15.0	1.0 - 8.0	0.0 - 76.0

* Patients may have multiple doses of oral corticosteroids. Percents are calculated out of the total number of doses of oral corticosteroid given.

+ p-value is for the comparison of A or C compared to B

Table x: Total corticosteroid dose taken per participant in each follow-up period (FAS)

Summary	Arm A N=27	Arm B N=19	Arm C N=10	Total N=56
up to Week 4				
n	3	0	0	3
Mean (SD)	336.7 (323.3)	NA	NA	336.7 (323.3)
Median	150.0	NA	NA	150.0
Q1,Q3	150.0, 710.0	NA, NA	NA, NA	150.0, 710.0
Min-Max	150.0 - 710.0	NA	NA	150.0 - 710.0
Week 4 up to Week 12				
n	6	4	1	11
Mean (SD)	125.0 (38.7)	225.0 (146.5)	215.0 (NA)	169.5 (99.1)
Median	125.0	180.0	215.0	150.0
Q1,Q3	100.0, 150.0	127.5, 322.5	215.0, 215.0	100.0, 210.0
Min-Max	75.0 - 175.0	105.0 - 435.0	215.0 - 215.0	75.0 - 435.0
Week 12 up to Week 24				
n	18	4	2	24
Mean (SD)	325.8 (267.9)	150.0 (0.0)	150.0 (0.0)	281.9 (243.1)
Median	200.0	150.0	150.0	150.0
Q1,Q3	150.0, 500.0	150.0, 150.0	150.0, 150.0	150.0, 500.0
Min-Max	0.0 - 880.0	150.0 - 150.0	150.0 - 150.0	0.0 - 880.0
Week 24				
n	6	3	1	10
Mean (SD)	179.0 (111.1)	116.7 (28.9)	20.0 (NA)	144.4 (99.1)
Median	160.0	100.0	20.0	150.0
Q1,Q3	150.0, 300.0	100.0, 150.0	20.0, 20.0	100.0, 170.0
Min-Max	4.0 - 300.0	100.0 - 150.0	20.0 - 20.0	4.0 - 300.0

Table x: Summary of oral corticosteroids taken during follow-up (FAS)

Medication name	Summary	Arm A N=6	Arm B N=5	Arm C N=2	Total N=13
PREDNISOLONE	Days medication taken				
	n	25	17	5	47
	Mean (SD)	10.1 (17.3)	8.7 (3.9)	4.8 (3.5)	9.0 (12.9)
	Median	5.0	7.0	7.0	7.0
	Q1,Q3	2.0, 7.0	7.0, 14.0	1.0, 7.0	3.0, 7.0
	Min-Max	0.0 - 76.0	5.0 - 15.0	1.0 - 8.0	0.0 - 76.0

Table x: Cumulative corticosteroid dose up to and at Week 24- excluding participants who withdrew before Week 24 (FAS)

Summary	Arm A N=45	Arm B N=29	Arm C N=29	Total N=103
n	43	28	27	98
Mean (SD)	179.9 (259.7)	132.9 (139.6)	70.6 (117.5)	136.3 (200.9)
Median	100.0	150.0	0.0	100.0
Q1,Q3	0.0, 250.0	0.0, 230.0	0.0, 150.0	0.0, 150.0
Min-Max	0.0 - 1246.5	0.0 - 490.0	0.0 - 520.0	0.0 - 1246.5
P-value+	0.922		0.05	

+p-value is for the comparison of A or C compared to B

Safety Analyses

Adverse Events

Table x Adverse Events by study arm (FAS)

	Arm A N=45	Arm B N=29	Arm C N=29	Total N=103
All Adverse Events				
Total	140	99	77	316
N experiencing at least one event	39	28	25	92
Serious Adverse Events				
Total	1	2	2	5
N experiencing at least one event	1	2	2	5

Table x SAE descriptions (FAS)

Study ID	Study Arm	*Description
57	A	"Admitted to surgical assessment until for 2 days with abdominal pain. had 2 days of Intravenous abx and fluids. CT showed no significant findings. patient discharged with no treatment. diagnosis: unspecific abdominal pain"
104	C	"SURGERY : Excision Transformation Zone (large loop)"
106	B	"Fainted at church, unconscious for 2minutes, received CPR"
116	B	"left Dupuytren's fasciectomy"
121	C	"Cholecystitis on CBD stones"

*Descriptions are reported as recorded in MACRO